| INTRODUC TI ON
, an infectious disease caused by Mycobacterium tuberculosis, remains a major threat to human health in terms of worldwide morbidity and mortality (World Health Organization, 2018) .
Currently, the number of TB deaths and new TB cases are continuously increasing each year, and the new TB epidemic was assessed in the 2018 Global Tuberculosis Report (World Health Organization, 2018) D-Alanyl-D-alanine ligase A (DdlA) is an attractive potential anti-TB drug target (Yang et al., 2018) . DdlA catalyses the ATP-dependent dimerization of two D-alanine molecules to yield D-alanyl-D-alanine, which is required for the biosynthesis of peptidoglycan (PG); PG is essential for preserving cell integrity by preserving internal osmotic pressure and maintaining the defined cell morphology and cell division (Bruning, Murillo, Chacon, Barletta, & Sacchettini, 2011; Kieser et al., 2015; Yang et al., 2018) . Theoretically, the biosynthesis of PG is an ideal target for anti-TB drug design because the complete path- (Barreteau et al., 2008; Macheboeuf, Contreras-Martel, Job, Dideberg, & Dessen, 2006; Yang et al., 2018) . The crosslinked PG confers tensile strength to the bacterial cell wall. Thus, the inhibition of PG crosslinking causes extensive cell wall weakening or cell death; DdlA is involved in PG crosslinking by supplying the indispensable D-alanyl-D-alanine. In addition, compounds with structural similarity to D-alanine can competitively inhibit DdlA activity with fewer side effects, because D-alanine is absent in humans. Therefore, in combination with the essentiality of the ddlA gene in M. tuberculosis, the characteristics of DdlA make it an ideal target for anti-TB drugs.
In fact, the particularly interesting nature of DdlA as a novel anti-TB drug target that has been indicated by the clinical application of D-cycloserine as an effective second-line antibiotic against M. tuberculosis (Halouska et al., 2014; McCoy & Maurelli, 2005; Prosser & de Carvalho, 2013) . However, the use of D-cycloserine, which targets DdlA and alanine racemase as structural analogues of D-alanine, is restricted in TB treatment because of its serious neurological side effects (Yang et al., 2018) . D-Cycloserine overdose has been reported to cause central nervous system side effects such as drowsiness, headaches, vertigo, depression, paraesthesias, dizziness, dysarthria, confusion, hyperirritability, convulsions, psychosis, tremors, paresis, seizures, and coma by activating the N-methyl-D-aspartate-type glutamate receptor (Chen, Uplekar, Gordon, & Cole, 2012; Halouska et al., 2014; Schade & Paulus, 2016) . To design a nontoxic compound that targets DdlA and to better understand the roles of DdlA in mycobacteria in vivo, an extensive study on DdlA was performed using a Mycobacterium smegmatis model of DdlA downregulation induced by Sm-ddlA antisense RNA.
| MATERIAL S AND ME THODS

| Strains and plasmids
The properties of the plasmids and bacterial strains used in this study are shown in 
| Gene manipulation and protein expression
Mycobacterium smegmatis genomic DNA was used as a PCR template to amplify Sm-ddlA (MSMEG_2395), yielding a 1,122 bp DNA fragment. Then, the purified PCR product was cloned into pMD18-T, generating the pMD18-Sm-ddlA plasmid. Following sequence confirmation, Sm-ddlA was digested for subsequent ligation into pCold II (Takara, China) to generate pCold II-Sm-ddlA, which was transformed into E. coli BL21(DE3) for DdlA expression. The preparation of cell lysates and the purification and detection of DdlA were conducted as described previously (Yang et al., 2018) .
| Production of the antibody against M. smegmatis DdlA
Purified DdlA was used to immunize mice to produce the anti- 
| M. smegmatis cell growth assays
M. smegmatis cells carrying pMind-Sm-ddlA-AS were grown in LB broth.
Tetracycline was added as an inducer at gradient concentrations of 0 ng/ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, and 50 ng/ml. in LB broth containing 20 ng/ml tetracycline were used as the control.
| Detection of endogenous DdlA
Mycobacterium smegmatis cells carrying pMind-Sm-ddlA-AS were grown in LB broth containing tetracycline at concentrations of 20 ng/ml and 0 ng/ml. The cells were harvested after shaking for 36 hr, and cell lysates were extracted as described previously (Yang et al., 2018 onto 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred onto a nitrocellulose (NC) membrane for WB analysis. The transferred membrane was probed by incubating with a polyclonal antibody against DdlA at a 1:2,000 dilution, followed by incubation with an anti-mouse IgG HRP-conjugated secondary antibody. The target DdlA bands were visualized using enhanced chemiluminescence (ECL) reagents. M. smegmatis cells carrying pMind and grown in LB broth containing 20 ng/ml or 0 ng/ml tetracycline were used as the controls.
| Morphological observation
Mycobacterium smegmatis cells carrying pMind-Sm-ddlA-AS and grown in LB broth containing 20 ng/ml tetracycline were harvested.
Then, the harvested cells were fixed in 2.5% glutaraldehyde in 0.1 mmol/ml phosphate buffer (PBS, pH 7.4). Postfixation was performed in 1% osmium tetroxide (OsO 4 ) in PBS, followed by dehydration in a graded series of ethanols (20%, 40%, 60%, 70%, 80%, 90%, and 100%). The subsequent transmission electron microscopy (TEM) and scanning electron microscopy (SEM) analyses were conducted as described previously (Zhang et al., 2008) .
| Protein processing, bidimensional gel electrophoresis and image analysis
Soluble protein was extracted from the harvested M. smegmatis cells carrying pMind-Sm-ddlA-AS and processed using a clean-up kit according to the manufacturer's instructions (Bio-Rad). The protein pellets were dissolved in 50 μl of isoelectric focusing (IEF) buffer (7 mol/L urea, 2 mol/L thiourea, 2% (w/v) CHAPS, and 30 mmol/L Tris, pH 8.0), and the total soluble protein was quantified using a BCA kit. Fifty micrograms of total soluble protein was subjected to bidimensional difference in gel electrophoresis (2D-DIGE). Proteins were separated in the first dimension according to their pI using Immobiline DryStrips (11 cm, pH 4-7, Bio-Rad) and in the second dimension according to their molecular weight using 12% SDS-PAGE gels. The gels were stained using a ProteoSilver Plus SilverStain Kit (Sigma). Image analysis and statistical quantification of relative protein abundances were performed using PDQuest software. Student's t test was performed to assess the statistical significance of differentially expressed proteins based on the average spot volume ratio. The protein spots that met the criteria of a fold change (FC) ≥2 or ≤0.5 at a 95% confidence level (Student's t test; p < 0.05) were selected for further identification by mass spectrometry (MS). Spots located near the gel borders and small or faint spots were excluded from protein identification. M. smegmatis cells carrying pMind were used as the control in this study. The experiment was performed in triplicate.
| Trypsin digestion, MS/MS analysis and data acquisition
The selected protein spots were excised manually from the gels for MS analysis. The subsequent trypsin digestion and MS/MS analysis were performed as described previously (Yang et al., 2018) . Proteomic data were acquired using Mascot 2.2 software.
The obtained MS/MS spectra were searched against the NCBI database. Confidence in the peptide identifications was assessed based on the Mascot sequence assignment score and visual inspection of the molecular mass and pI values of the selected spots from the gels. Figure 1a,b) . The SDS-PAGE and WB analyses confirmed that a soluble DdlA fusion protein had been obtained.
| Bioinformatic analysis
Female BALB/c mice were immunized with the pure recombinant DdlA antigen and sacrificed to obtain serum for testing the specificity of the anti-DdlA antibody. Figure 1c shows that the produced anti-DdlA antibody specifically interacted with the recombinant DdlA protein antigen. In addition, the optimum titer of 1:2,000 for the produced antibody was determined using ELISA. Therefore, the anti-DdlA antibodies produced in this study can respond specifically against the DdlA antigen and are applicable for DdlA detection. Therefore, the TEM images indicate that a rearrangement of intracellular content and an increase in the number of Z rings numbers occur in mycobacteria due to DdlA deficiency.
| Identification of differentially expressed proteins by 2D-DIGE coupled with MS/MS analysis
Proteomic changes were automatically analyzed by PDQuest software. Figure 5 shows the paired 2D-DIGE images, which were labeled manually with the numbers obtained from the PDQuest analysis. As a consequence, 53 filtered protein spots with fold changes in expression of >2 or <0.05 displayed significant changes between the paired groups (p < 0.05). Of the 53 protein spots, 12 were differentially upregulated, whereas 41 were differentially downregulated in the M.
smegmatis cell model. Considering the spot intensities and locations on the 2D-DIGE images, 22 spots, which corresponded to the most highly differentially expressed proteins in terms of fold change and/ or statistical significance, were chosen for identification by MS/MS.
Twenty-two spots with the remarkable intensity changes were further extracted from the gel and identified by MS. Table 2 shows F I G U R E 1 Identification of the purified DdlA by SDS-PAGE (a) and WB (b) and specificity testing of the anti-DdlA polyclonal antibody by WB (c). M, PageRuler prestained protein ladder (Fermentas). Colorimetric visualization was performed using BCIP/NBT solution in the WB analysis (a and c) and Coomassie in the SDS-PAGE analysis (b). The monoclonal anti-polyhistidine antibody at a 1:5,000 dilution was used to probe the expressed DdlA (a); the produced polyclonal anti-DdlA antibody at a 1:2,000 dilution was used to probe the purified DdlA (c). a and b, 1-2, the fractions of the purified DdlA. c, 1, purified Mycobacterium smegmatis DdlA (Cambridge, Blinkova, Magnan, Bates, & Walker, 2014; Marteyn et al., 2014; Szwedziak, Wang, Bharat, Tsim, & Jan, 2014) . However, the mechanism by which DdlA influences mycobacterial division remains to be determined. Additionally, the morphological images showed that although DdlA deficiency could not directly lead F I G U R E 2 Confirmatory analysis of inhibited cell growth and decreased endogenous DdlA expression in vivo. Cell growth was monitored at 12-hr intervals, and the values plotted are the means and standard deviations of triplicate experiments. (a) Growth curve of Mycobacterium smegmatis cells carrying pMind-Sm-ddlA-AS grown with tetracycline concentrations of 0 ng/ml, 5 ng/ml, 10 ng/ml, 20 ng/ ml, 30 ng/ml and 50 ng/ml; (b) Growth curve of M. smegmatis cells carrying pMind grown with tetracycline concentrations of 0 ng/ml, 5 ng/ ml, 10 ng/ml, 20 ng/ml, 30 ng/ml, and 50 ng/ml; ( bonds from methanol assimilation (Harm, Harm, & Dijkhuizen, 2000) . In this study, MSMEG_6242 was found to directly interact with MSMEG_1735, MSMEG_6008, MSMEG_1665, and In this study, the most highly differentially expressed protein was MSMEG_1419, which was highly upregulated when M.
smegmatis was grown under DdlA deficiency. MSMEG_1419 encodes fumonisin, which usually exists in contaminated maize (Brown, Butchko, Busman, & Proctor, 2007) . Fumonisin, a notorious mycotoxin, consists of aminopolyols with a core structure containing a 19-or 20-carbon backbone with methyl, hydroxyl, and tricarballylic acid moieties at different sites along the carbon backbone (Baird et al., 2008) . Currently, accumulating evidence shows that fumonisin, which is a polyketide derivative and is structurally related to sphinganine, usually causes a variety of toxicological effects, such as esophageal cancer, cardiovascular problems, and neural tube defects, in humans and animals (Desjardins, Munkvold, Plattner, & Proctor, 2002; Waskiewicz, Stepien, Wilman, & Kachlicki, 2013 (Liu, Yang, & He, 2016; Titgemeyer et al., 2007) . In this study, into anti-TB drug design to combat the difficult-to-treat pathogen M. tuberculosis. and fumonisin (MSMEG_1419) were the identified proteins with the greatest differential expression; these proteins have substantial potential to be developed into anti-TB drug targets. Therefore, our dataset provides intriguing insight into antimycobacterial drug design via developing novel anti-TB drug targets which were revealed in this study. 
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